ImmuPharma (LON:IMM) Trading Up 14.3% - Still a Buy?

Key Points

• ImmuPharma's share price rose by 14.3%, reaching a last traded price of GBX 12.46 ($0.17) after closing at GBX 10.90 ($0.15).
• The company reported a negative return on equity of 131.41% and a remarkable net margin of 3,519.56% for the recent quarter.
• ImmuPharma focuses on developing peptide-based therapeutics, with its lead program targeting Lupus and potential applications for other autoimmune diseases.

ImmuPharma plc (LON:IMM - Get Free Report)'s share price was up 14.3% during trading on Thursday . The stock traded as high as GBX 13.95 ($0.19) and last traded at GBX 12.46 ($0.17). Approximately 2,830,881 shares were traded during mid-day trading, a decline of 66% from the average daily volume of 8,358,668 shares. The stock had previously closed at GBX 10.90 ($0.15).

ImmuPharma Stock Up 11.5%

The company has a market capitalization of £61.08 million, a price-to-earnings ratio of -13.65 and a beta of 1.53. The company has a 50 day simple moving average of GBX 8.52 and a 200 day simple moving average of GBX 4.55.

ImmuPharma (LON:IMM - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported GBX (0.38) EPS for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. On average, research analysts forecast that ImmuPharma plc will post -339.0000022 EPS for the current fiscal year.

About ImmuPharma

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.